Abstract
Chordoma is a relatively rare malignant bone tumor that is considered to arise in the remnant of the embryonic notochord. Chordoma retains both epithelial and mesenchymal characters. Anti-Cytokeratin, CAM5.2 that mainly reacts with Moll’s peptide #8 has been most often used for researches in cell differentiation or in clinicopathology. Since 1980s, immunohistochemical analysis of the expression of cytokeratins including CAM5.2 has been considered useful for discriminating chordoma from chondrosarcoma because the two tumors resemble each other in both radiologic and histologic findings. In contrast to chondrosarcoma, which shows completely negative immunoreactivity for cytokeratins, chordoma exhibits positive cytokeratin expression. However, immunoreactivity for CAM5.2 varies from case to case in contrast to pancytokeratin which is usually strongly expressed in entire lesions of chordoma. In addition, clinicopathologic significance of CAM5.2 expression is unknown in chordoma. Previous reports indicated the correlation of CAM5.2 expression with several clinicopathological parameters and a significance of CAM5.2 expression in the biology of chordoma. This review offers an overview of the role of CAM5.2 expression in chordoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abenoza P, Sibley RK (1986) Chordoma: an immunohistologic study. Hum Pathol 17:744–747
Coindre JM, Rivel J, Trojani M, Mascarel I, Mascarel A (1986) Immunohistological study in chordomas. J Pathol 50:61–63
Cooper C, Park M, Blair D, Tainsky M, Huebner K, Croce C (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29–33
Debernardi L (1913) Cordoma sacromatoso del sacro contributo all conoscanza istologica e clinica dei tumori di origine cordale. Arch Sci Med 37:404–456
Di Renzo MF, Narsimhan RP, Oliviero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM (1991) Expression of the Met/HGF receptor in normal and neoplastic human tissue. Oncogene 6:1997–2003
Grigioni W, Fiorentino M, D’Errico A, Ponzetto A, Crepaldi T, Prat M (1995) Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology 21:1543–1546
Hecht M, Papoutsi M, Tran HD, Wilting J, Schweigerer L (2004) Hepatocyte growth factor/c-MET signaling promotes the progression of experimental human neuroblastomas. Cancer Res 64:6109–6118
Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW (1973) Chordomas and cartilaginous tumors at the skull base. Cancer 32:410–420
Imai R, Kamada T, Tsuji H, Sugawara S, Serizawa I, Tsujii H, Tatezaki SI, Working Group for Bone and Soft Tissue Sarcomas (2010) Effect of carbon ion radiotherapy for sacral chordoma: results of phase I-II and phase II clinical trials. Int J Radiat Oncol Biol Phys 77(5):1470–1476
Kumaki F, Matsui K, Kawai T, Ozeki Y, Yu ZX, Ferrans VJ, Travis WD (2001) Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 159:2125–2135
Listrom MB, Dalton LW (1987) Comparison of keratin monoclonal antibodies MAK-6, AE1/AE3, and CAM5.2. Am J Surg Pathol 11:516–525
Meis JM, Raymond AK, Evans HL, Charles RE, Giraldo AA (1987) “Dedifferentiated” chordoma: a clinicopathologic and immunohistochemical study of three cases. Am J Surg Pathol 11:516–525
Michalopoulos GK (1990) Liver regeneration: molecular mechanisms of growth control. FASEB J 4:176–187
Moll R, Franke W, Schiller D, Geiger B, Krepler R (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors, and cultured cells. Cell 31:11–24
Montesano R, Matsumono K, Nakamura T, Orci L (1991) Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67:901–908
Naka T, Iwamoto Y, Shinohara N, Chuman H, Fukui M, Tsuneyoshi M (1997a) Cytokeratin subtyping in chordomas and the fetal notochord: an immunohistochemical analysis of aberrant expression. Mod Pathol 10:545–551
Naka T, Iwamoto Y, Shinohara N, Ushijima M, Chuman H, Tsuneyoshi M (1997b) Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol 10:832–838
Naka T, Boltze C, Kuester D, Schulz T-O, Samii A, Herold C, Ostertag H, Roessner A (2004) Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol 122:926–930
Naka T, Boltze C, Kuester D, Samii A, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Roessner A (2005) Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions. Am J Clin Pathol 124:288–294
Naka T, Kuester D, Boltze C, Schulz T-O, Samii A, Herold C, Ostertag H, Roessner A (2008a) Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum Pathol 39:217–223
Naka T, Kuester D, Boltze C, Scheil S-B, Samii A, Herold C, Ostertag H, Krueger S, Roessner A (2008b) Expression of hepatocyte growth factor and c-MET in skull base chordoma. Cancer 112:104–110
Naka T, Boltze C, Samii A, Samii M, Herold C, Ostertag H, Iwamoto Y, Oda Y, Tsuneyoshi M, Kuester D, Roessner A (2009) Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma. Histopathology 54:607–613
Nakapoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, Davaris PS (2000) c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology 36:313–325
Obermajer N, Doljak B, Kos J (2009) Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. Mol Cancer 8:88
Pena CE, Horvat BL, Fisher ER (1970) The ultrastructure of chordoma. Am J Clin Pathol 53:544–551
Rosenberg AE, Brown GA, Bhan AK, Lee JM (1994) Chondroid chordoma: a variant of chordoma: a morphological and immunohistochemical study. Am J Clin Pathol 101:36–41
Salisbury JR, Isaacson PG (1985) Demonstration of cytokeratins and an epithelial membrane antigen in chordomas and human fetal notochord. Am J Surg Pathol 9:791–797
Smith J, Ludwig RL, Marcove RC (1987) Sacrococcygeal chordoma: a clinicoradiological study of 60 patients. Skeletal Radiol 16:37–44
Sonnenberg E, Meyer D, Weider K, Birchmeier C (1993) Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123:223–235
Stoker M, Gherardi E, Perryman M, Gray J (1987) Scatter factor is a fibroblast-derived modulator of epithelial cell motility. Nature 327:239–242
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Naka, T. (2012). Chordoma: Role of CAM5.2. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 8. Tumors of the Central Nervous System, vol 8. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4213-0_17
Download citation
DOI: https://doi.org/10.1007/978-94-007-4213-0_17
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4212-3
Online ISBN: 978-94-007-4213-0
eBook Packages: MedicineMedicine (R0)